You need to enable JavaScript to run this app.
EMA to address nitrosamine impurities in upcoming revision of active substances guidance
Regulatory News
Joanne S. Eglovitch
APIs
Europe
Pharmaceuticals
Regulatory NewsJoanne S. Eglovitch
APIsEuropePharmaceuticalsRegulatory NewsJoanne S. EglovitchAPIsEuropePharmaceuticals